SCROLL TO CONTINUE WITH CONTENT

Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Log in
Register
Log in
Subscribe
Claim

Skip menu

theclinics.com
Articles
- Latest
- Popular Articles
  
  Review Article
  The Cardiovascular Manifestations of COVID-19
  Louis et al.
  Review Article
  Open Access
  Oxygen Therapy in Pulmonary Vascular Disease: A Systematic Review, Meta-Analysis, and Comment
  Schuster et al.
  Review Article
  A Review of Heart Failure in patients with COVID-19
  Bashir et al.
- Latest Articles
  
  Review Article
  The Cardiovascular Manifestations of COVID-19
  Louis et al.
  Review Article
  Use and Prognostic Implications of Cardiac Troponin in COVID-19
  De Michieli et al.
  Review Article
  Review of Immunologic Manifestations of COVID-19 Infection and Vaccination
  Pozdnyakova et al.
Publish
- For Authors
  - Guide for Authors
    External Link
  - Aims & Scope
Multimedia
- - Clinics Review Articles Podcast
    External Link
About
- Journal Information
- Access
Contact
- Contact
- Follow Us
  - New Content Alerts
  - Twitter
    External Link

Advanced search

Please enter a term before submitting your search.

October 2022

Volume 18Issue 4p529-654

SGLT-2 Inhibitors

Edited byRagavendra R. Baliga, Deepak L. Bhatt

Current Issue
Articles in Press
Archive
- Archive

Previous IssueTranslational Research in Cardio-Oncology

Next IssueChallenges in Pulmonary Hypertension

Select all

Download started.
Ok

Please select at least one article in order to proceed.

Miscellaneous

SGLT-2 Inhibitors

Ragavendra R. Baliga,
Deepak L. Bhatt

Published in issue: October 2022

Full-Text HTML
PDF

Copyright

Published in issue: October 2022

Full-Text HTML
PDF

Contributors

Published in issue: October 2022

iii-v

Full-Text HTML
PDF

Contents list

Published in issue: October 2022

vii-ix

Full-Text HTML
PDF

Editorial

SGLT2 Inhibitors Are Lifesavers in Heart Failure

Ragavendra R. Baliga,

Deepak L. Bhatt,

Eduardo Bossone

Published in issue: October 2022

xi-xiv

Full-Text HTML
PDF

Review article

Glucose-Lowering and Metabolic Effects of SGLT2 Inhibitors

Ify R. Mordi,
Chim C. Lang

Published in issue: October 2022

p529-538

Full-Text HTML
PDF

Renoprotective Effects of SGLT2 Inhibitors

Volker Vallon

Published in issue: October 2022

p539-549

Full-Text HTML
PDF

SGLT2 Inhibitors in Type 2 Diabetes Mellitus

Giulia Ferrannini,
Gianluigi Savarese,
Francesco Cosentino

Published in issue: October 2022

p551-559

Open Access

Full-Text HTML
PDF

SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction

A Paradigm Shift Toward Dual Cardio-Renal Protection

Tripti Rastogi,
Nicolas Girerd

Published in issue: October 2022

p561-577

Full-Text HTML
PDF

SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction

Pardeep S. Jhund

Published in issue: October 2022

p579-586

Full-Text HTML
PDF

SGLT2 Inhibitors in Heart Failure

Early Initiation to Achieve Rapid Clinical Benefits

Neal M. Dixit,
Boback Ziaeian,
Gregg C. Fonarow

Published in issue: October 2022

p587-596

Full-Text HTML
PDF

Sodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease Events

Adam J. Nelson,
Josephine L. Harrington,
Ahmed A. Kolkailah,
Neha J. Pagidipati,
Darren K. McGuire

Published in issue: October 2022

p597-607

Full-Text HTML
PDF

SGLT2 Inhibitors and Peripheral Vascular Events

A Review of the Literature

Elena Marchiori,
Roman N. Rodionov,
Frederik Peters,
...
Konstantinos Spanos,
Natalia Jarzebska,
Christian-Alexander Behrendt

Published online: August 12, 2022

p609-623

Full-Text HTML
PDF

Sodium-glucose Cotransporter 2 Inhibitors and Nonalcoholic Fatty Liver Disease

Husam M. Salah,
Marat Fudim

Published in issue: October 2022

p625-634

Full-Text HTML
PDF

SGLT2 Inhibitors and Safety in Older Patients

Rena Pollack,
Avivit Cahn

Published in issue: October 2022

p635-643

Full-Text HTML
PDF

Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk

Clare Arnott,
Robert A. Fletcher,
Bruce Neal

Published in issue: October 2022

p645-654

Full-Text HTML
PDF

Login to your account

Email/Username

Password

Show

Forgot password?

Remember me

Don’t have an account?

Create a Free Account

If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password

Email*

If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password

Cancel

theclinics.com
Home
Articles & Issues
Articles in Press
Buy Back Issues
Current Issue
Future Issues
Past Issues
For Authors
Author Information
Series Information
About
Contact Information
Media Information
Pricing Information
Subscribe

The content on this site is intended for healthcare professionals.

We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.

Privacy Policy
Terms and Conditions
Accessibility
Help & Contact

Latest

Popular Articles

The Cardiovascular Manifestations of COVID-19

Oxygen Therapy in Pulmonary Vascular Disease: A Systematic Review, Meta-Analysis, and Comment

A Review of Heart Failure in patients with COVID-19

Latest Articles

The Cardiovascular Manifestations of COVID-19

Use and Prognostic Implications of Cardiac Troponin in COVID-19

Review of Immunologic Manifestations of COVID-19 Infection and Vaccination

For Authors

Journal Information

Access

Contact

Follow Us

October 2022

Miscellaneous

SGLT-2 Inhibitors

Copyright

Contributors

Contents list

Contents

Other contents

Forthcoming Issues

Editorial

SGLT2 Inhibitors Are Lifesavers in Heart Failure

Review article

Glucose-Lowering and Metabolic Effects of SGLT2 Inhibitors

Renoprotective Effects of SGLT2 Inhibitors

SGLT2 Inhibitors in Type 2 Diabetes Mellitus

SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction

A Paradigm Shift Toward Dual Cardio-Renal Protection

SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction

SGLT2 Inhibitors in Heart Failure

Early Initiation to Achieve Rapid Clinical Benefits

Sodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease Events

SGLT2 Inhibitors and Peripheral Vascular Events

A Review of the Literature

Sodium-glucose Cotransporter 2 Inhibitors and Nonalcoholic Fatty Liver Disease

SGLT2 Inhibitors and Safety in Older Patients

Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk